MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Reduces Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lessened its stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 5.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 21,386 shares of the specialty pharmaceutical company’s stock after selling 1,204 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in KalVista Pharmaceuticals were worth $181,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Aquatic Capital Management LLC purchased a new stake in KalVista Pharmaceuticals during the 4th quarter worth approximately $44,000. Tower Research Capital LLC TRC grew its position in KalVista Pharmaceuticals by 666.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company’s stock worth $54,000 after purchasing an additional 5,502 shares during the last quarter. Legal & General Group Plc grew its position in KalVista Pharmaceuticals by 22.5% during the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock worth $69,000 after purchasing an additional 1,494 shares during the last quarter. Martin Worley Group purchased a new stake in KalVista Pharmaceuticals during the 4th quarter worth approximately $86,000. Finally, China Universal Asset Management Co. Ltd. grew its position in KalVista Pharmaceuticals by 24.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock worth $87,000 after purchasing an additional 2,043 shares during the last quarter.

Insiders Place Their Bets

In other news, insider Paul K. Audhya sold 2,776 shares of the company’s stock in a transaction on Monday, May 19th. The shares were sold at an average price of $11.84, for a total transaction of $32,867.84. Following the completion of the sale, the insider now owns 106,611 shares of the company’s stock, valued at $1,262,274.24. This represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Venrock Healthcare Capital Par bought 25,000 shares of the company’s stock in a transaction dated Wednesday, April 9th. The shares were acquired at an average cost of $9.42 per share, with a total value of $235,500.00. Following the acquisition, the insider now directly owns 5,303,985 shares of the company’s stock, valued at approximately $49,963,538.70. This represents a 0.47% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 15,399 shares of company stock worth $182,054. Company insiders own 10.50% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Needham & Company LLC reissued a “buy” rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 8th. Jones Trading restated a “buy” rating and set a $30.00 price objective on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, KalVista Pharmaceuticals currently has an average rating of “Buy” and an average price target of $24.83.

KalVista Pharmaceuticals Trading Down 1.1%

Shares of NASDAQ KALV opened at $11.76 on Monday. The company has a 50 day simple moving average of $11.90 and a two-hundred day simple moving average of $10.47. KalVista Pharmaceuticals, Inc. has a 12 month low of $7.30 and a 12 month high of $15.50. The stock has a market cap of $584.66 million, a price-to-earnings ratio of -3.23 and a beta of 0.05.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).